IL155178A0 - Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation - Google Patents

Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation

Info

Publication number
IL155178A0
IL155178A0 IL15517801A IL15517801A IL155178A0 IL 155178 A0 IL155178 A0 IL 155178A0 IL 15517801 A IL15517801 A IL 15517801A IL 15517801 A IL15517801 A IL 15517801A IL 155178 A0 IL155178 A0 IL 155178A0
Authority
IL
Israel
Prior art keywords
mutants
preparation
multiple sclerosis
chemokine
new
Prior art date
Application number
IL15517801A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL155178A0 publication Critical patent/IL155178A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15517801A 2000-10-04 2001-10-03 Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation IL155178A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
IL155178A0 true IL155178A0 (en) 2003-11-23

Family

ID=8170011

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15517801A IL155178A0 (en) 2000-10-04 2001-10-03 Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation
IL155178A IL155178A (en) 2000-10-04 2003-04-01 Use of Kamokin mutants to prepare a drug for the treatment of multiple sclerosis, such new mutants and their preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155178A IL155178A (en) 2000-10-04 2003-04-01 Use of Kamokin mutants to prepare a drug for the treatment of multiple sclerosis, such new mutants and their preparation

Country Status (30)

Country Link
US (1) US7402303B2 (sr)
EP (1) EP1326628B1 (sr)
JP (1) JP3908165B2 (sr)
KR (1) KR100837898B1 (sr)
CN (1) CN1285381C (sr)
AR (1) AR030854A1 (sr)
AT (1) ATE265222T1 (sr)
AU (2) AU2002215919B2 (sr)
BG (1) BG66137B1 (sr)
BR (1) BR0114407A (sr)
CA (1) CA2423616C (sr)
CZ (1) CZ303409B6 (sr)
DE (1) DE60103078T2 (sr)
DK (1) DK1326628T3 (sr)
EA (1) EA006137B1 (sr)
EE (1) EE05174B1 (sr)
ES (1) ES2217199T3 (sr)
HR (1) HRP20030215B1 (sr)
HU (1) HUP0302194A3 (sr)
IL (2) IL155178A0 (sr)
MX (1) MXPA03003008A (sr)
NO (1) NO330278B1 (sr)
PL (1) PL204231B1 (sr)
PT (1) PT1326628E (sr)
RS (1) RS50738B (sr)
SI (1) SI1326628T1 (sr)
SK (1) SK287523B6 (sr)
UA (1) UA77950C2 (sr)
WO (1) WO2002028419A2 (sr)
ZA (1) ZA200302315B (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468790A1 (en) 2001-12-17 2003-06-26 Applied Research Systems Ars Holding N.V. Chemokine mutants acting as chemokine antagonists
AU2003240758B2 (en) 2002-04-04 2008-03-13 Laboratoires Serono Sa Chemokines mutants having improved oral bioavailability
DE60320848D1 (de) * 2002-12-23 2008-06-19 Serono Lab Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen
US20090022657A1 (en) * 2003-10-22 2009-01-22 Applied Research Systems Ars Holding N.V. Novel CXCL8 antagonists
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
PT1439191E (pt) * 2004-01-19 2006-06-30 Ares Trading Sa Processo para a purificacao de proteinas expressas de forma bacteriana
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
WO2009054873A2 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
CA2788902C (en) * 2010-02-08 2019-09-03 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
CN112469430B (zh) 2018-05-28 2024-12-24 日内瓦大学 抑制大脑炎症的方法
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
ATE308617T1 (de) 1997-12-23 2005-11-15 San Raffaele Centro Fond Rantes mutanten und deren therapeutischen anwendungen
CA2361256A1 (en) * 1999-01-29 2000-08-03 James B. Rottman Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
HRP20030215A2 (en) 2005-02-28
IL155178A (en) 2009-07-20
JP2004510426A (ja) 2004-04-08
HUP0302194A2 (hu) 2003-10-28
WO2002028419A3 (en) 2002-06-13
CN1477969A (zh) 2004-02-25
HRP20030215B1 (en) 2011-09-30
US7402303B2 (en) 2008-07-22
DE60103078D1 (de) 2004-06-03
SK4062003A3 (en) 2003-08-05
SI1326628T1 (en) 2004-10-31
NO20031525L (no) 2003-04-03
CZ2003947A3 (cs) 2003-11-12
CN1285381C (zh) 2006-11-22
ATE265222T1 (de) 2004-05-15
RS50738B (sr) 2010-08-31
SK287523B6 (sk) 2011-01-04
BG107685A (bg) 2003-11-28
HK1062811A1 (en) 2004-11-26
PL362350A1 (en) 2004-10-18
DE60103078T2 (de) 2005-04-07
EE200300139A (et) 2003-06-16
ZA200302315B (en) 2004-03-25
CA2423616A1 (en) 2002-04-11
WO2002028419A2 (en) 2002-04-11
ES2217199T3 (es) 2004-11-01
NO20031525D0 (no) 2003-04-03
DK1326628T3 (da) 2004-08-09
EA006137B1 (ru) 2005-10-27
BG66137B1 (bg) 2011-07-29
AU2002215919B2 (en) 2005-11-24
AU1591902A (en) 2002-04-15
AR030854A1 (es) 2003-09-03
CA2423616C (en) 2010-03-16
JP3908165B2 (ja) 2007-04-25
CZ303409B6 (cs) 2012-09-05
EP1326628A2 (en) 2003-07-16
EA200300439A1 (ru) 2003-08-28
HUP0302194A3 (en) 2005-12-28
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
EE05174B1 (et) 2009-06-15
BR0114407A (pt) 2003-07-29
MXPA03003008A (es) 2003-07-14
US20040101509A1 (en) 2004-05-27
EP1326628B1 (en) 2004-04-28
UA77950C2 (en) 2007-02-15
PL204231B1 (pl) 2009-12-31
YU25703A (sh) 2006-05-25
NO330278B1 (no) 2011-03-21
PT1326628E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
AU2001253456A1 (en) Antithrombogenic membrane mimetic compositions and methods
HUP0104496A3 (en) Compositions comprising 1,1,1,3,3-pentafluorobutane and use of said compositions
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
IL155178A0 (en) Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation
ZA978089B (en) 3,4-diaryloxazolone derivatives, their methods of preparation, and their use in therapeutics.
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
MXPA02000779A (es) Factor de activacion de la citocina altamente purificada y metodos de uso.
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
AU8975701A (en) Novel composition and use
IL147414A0 (en) Ifnar2 mutants, their production and use
HUP0102988A3 (en) Peroxides, their preparation process and use
AU9528798A (en) New triplex forming oligonucleotides and their use in anti-hbv
AU2001235003A1 (en) Novel human lysozymes and polynucleotides encoding the same
AU2001289281A1 (en) Novel polypeptide--- a human hepatic nuclear factor 12 and polynucleotide encoding it
AU5104101A (en) Composition and use
AU2001269106A1 (en) Novel alpha expressed in heart and testis
PL353004A1 (en) Novel calpains and their use
AU7660601A (en) Pseudo-metalloproteins, their preparation and use
HUP0104267A3 (en) 1,4-diaryl-2-fluoro-1-buten-3-ol compounds and their use in the preparation of 1,4-diaryl-2-fluoro-1,3-butadiane and 1,4-diaryl-2-fluoro-2-butene compounds
GB0014191D0 (en) Use and combined preparation
GB0013238D0 (en) Novel composition and use
GB0106809D0 (en) Organomagnesium fluorides and preparation of
HK1057490A (en) Osteopontin-coated surfaces and methods of use
GB9826894D0 (en) Chemokine and uses thereof